NeOnc’s Boldest Test Yet: Child’s Early Improvement Puts NEO100 in the Spotlight with Compassionate-Use Milestone

DENVER, Oct. 16, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ: NTHI) delivered a deeply human clinical update that brings its investigational brain-cancer technology, expanding Abu Dhabi presence and high-profile banking appointment into sharper focus. The company reported that a critically ill three-year-old boy with an aggressive brain tumor is breathing independently without ventilator support and beginning to move his legs after receiving investigational intranasal NEO100 through NeOnc’s Compassionate Care program. The treatment is being administered outside the company’s pediatric clinical trial, following coordination with the child’s physicians and the Department of Health – Abu Dhabi. While a single compassionate-use case cannot establish that NEO100 caused the reported improvement, the decision to make an investigational treatment available to a critically ill child underscores the importance of the technology to NeOnc’s development strategy and raises the stakes for the company to demonstrate its potential through rigorous clinical research.